Merck KGaA moved to expand its RNAi portfolio by agreeing to buy Silence Therapeutics for $1.3 billion, giving the German drugmaker control of divesiran, a TMPRSS6-targeting siRNA in a Phase 2 SANRECO study for polycythemia vera. The deal is positioned as a near-term buildout in rare and specialty diseases, with Merck expecting to close in the first quarter of 2027, subject to approvals and customary conditions. Silence’s polycythemia vera program follows an August Phase 2 readout showing a responder rate of 87.5% with divesiran versus 18.8% for placebo through week 36, easing earlier investor skepticism around biomarker and efficacy signals. The transaction also underscores how RNA delivery and differentiation are increasingly driving larger scale corporate bets, as competitors push forward with alternating RNA modalities. The acquisition also raises the strategic stakes in a crowded rare-blood market where approved therapies and rival pipelines compete on durability, depth of response, and convenience. For investors and development teams, the emphasis is on transferring execution risk from earlier partnership stage into a Merck-controlled Phase 3 pathway. Finally, the news reflects a broader industry pattern: acquirers are paying for late-stage clinical probability in niche indications rather than purely platform exposure, particularly where dosing advantages or responder profiles can be validated quickly in pivotal trials.